SCHEMBL2275759

SCHEMBL2275759

O=C(O)Cc1cccc(Oc2ccc(Br)cc2C(S)c2nccs2)c1

nearest known ligand 0.44

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 1/20 0.41
CTSA P10619 12/20 0.41
PTGDR2 Q9Y5Y4 6/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3252521 0.85 PTGDR2 (0.40) PPARDCTSAPTGDR2
SCHEMBL2279373 0.83 PPARD (0.42) PPARDPTGDR2
SCHEMBL2282151 0.83 PPARD (0.38) PPARDPTGDR2
SCHEMBL2277996 0.77 PTGDR2 (0.40) PPARDPTGDR2
SCHEMBL2275762 0.77 PPARD (0.41) PPARDCTSAPTGDR2
SCHEMBL2282723 0.76 PTGDR2 (0.41) PPARDPTGDR2
SCHEMBL2280465 0.75 PPARD (0.40) PPARDCTSAPTGDR2
SCHEMBL2282376 0.74 PPARD (0.42) PPARDPTGDR2
SCHEMBL2281418 0.74 PPARD (0.43) PPARDPTGDR2
SCHEMBL3252525 0.73 SCN9A (0.46) PPARDPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US claimed
WO-2010003127-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO claimed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
WO-2010003127-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 PPARD 27/4885CTSA 2290/4885PTGDR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.